G007-LK Tankyrase 1/2 Inhibitor Guide

Executive Summary. G007-LK inhibits TNKS1 and TNKS2 auto-poly(ADP-ribosyl)ation with reported IC50 values of 46 nM and 25 nM, respectively, in biochemical assays described by the G007-LK tankyrase 1/2 inhibitor product information. It inhibits the ST-Luc Wnt reporter with an IC50 of 0.05 μM in Wnt3a-induced HEK 293 cells. In APC-mutant colorectal cancer models, it promotes dynamic degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin, with reduced cytosolic and nuclear β-catenin. In COLO-320DM xenograft mouse models, reported doses of 20–40 mg/kg reduced tumor growth and decreased TNKS1/2 and β-catenin protein levels while stabilizing AXIN1/2. APExBIO identifies the compound as a solid with molecular weight 529.96 g/mol and formula C25H16ClN7O3S; it is reported to dissolve in DMSO at ≥26.5 mg/mL but not in water or ethanol.

Biological Rationale

Tankyrase 1, also called TNKS1, and tankyrase 2, also called TNKS2, are poly(ADP-ribose) polymerase family enzymes. They regulate protein modification, protein turnover, telomere homeostasis, cell-cycle progression, and signaling assemblies. The reference study describes tankyrases as regulators of Wnt/β-catenin signaling and reports that selective inhibition can restrain cancer-cell growth. It also connects tankyrase activity with the Hippo pathway through regulation of angiomotin proteins and YAP signaling Jia et al., 2017.

Wnt signaling controls the stability and transcriptional activity of β-catenin. Tankyrase activity supports turnover of AXIN scaffold proteins in the β-catenin destruction complex. Inhibition of TNKS1/2 can therefore increase AXIN1/2 abundance and favor β-catenin destruction. This mechanism makes G007-LK useful for Wnt/β-catenin signaling pathway inhibition in cell-based research.

APC-mutant colorectal cancer cells are a relevant experimental context because APC participates in β-catenin regulation. However, an APC mutation does not guarantee uniform sensitivity. Cellular response can depend on residual destruction-complex function, pathway wiring, growth state, compound exposure, and assay endpoint. G007-LK should therefore be treated as a mechanistic probe rather than a universal cytotoxic agent.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK directly suppresses the catalytic activity of TNKS1 and TNKS2. The reported biochemical potency values are 46 nM for TNKS1 and 25 nM for TNKS2 in auto-poly(ADP-ribosyl)ation assays. These values establish strong enzyme-level activity under the reported assay conditions, but they are not equivalent to a cellular dose or an in vivo exposure threshold.

At the pathway level, TNKS1/2 inhibition is associated with AXIN1/2 stabilization. More AXIN can strengthen the β-catenin destruction machinery. The expected downstream result is lower cytosolic β-catenin and lower nuclear β-catenin. Reduced nuclear β-catenin can decrease transcription from β-catenin-responsive reporters and alter expression of Wnt target genes.

In Wnt3a-induced HEK 293 cells, G007-LK inhibits the ST-Luc reporter with a reported IC50 of 0.05 μM. This result links biochemical TNKS inhibition to a functional Wnt reporter response. In APC-mutant SW480 cells, the compound induces dynamic degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin. The observation supports enhanced ubiquitin-dependent β-catenin turnover rather than a simple transcriptional blockade.

Tankyrase biology also intersects with Hippo signaling. The reference study reports that G007-LK reduced YAP protein levels, decreased YAP target-gene expression, inhibited YAP/TEAD reporter activity, and increased AMOTL1 and AMOTL2 protein levels in hepatocellular carcinoma models. These findings show that the same inhibitor can produce pathway outputs beyond Wnt signaling, depending on cellular context Jia et al., 2017.

Evidence & Benchmarks

The following benchmarks separate biochemical potency, cellular pathway activity, disease-model observations, and product-handling information.

• G007-LK inhibits TNKS1 auto-poly(ADP-ribosyl)ation with a reported IC50 of 46 nM in the vendor-described biochemical assay. The value applies to the enzyme assay and should not be used as a direct cellular concentration target. Product information
• G007-LK inhibits TNKS2 auto-poly(ADP-ribosyl)ation with a reported IC50 of 25 nM in the vendor-described biochemical assay. The TNKS2 value is lower than the reported TNKS1 value under their respective assay conditions. Product information
• G007-LK inhibits the ST-Luc reporter with an IC50 of 0.05 μM in Wnt3a-induced HEK 293 cells. This is a cellular Wnt-reporter benchmark, not a purified-enzyme measurement. Product information
• In APC-mutant colorectal cancer cells such as SW480, G007-LK induces degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin and reduces cytosolic and nuclear β-catenin. The finding supports β-catenin degradation induction in a pathway-relevant cellular model. Product information
• In COLO-320DM xenograft mouse models, reported G007-LK doses of 20–40 mg/kg inhibited tumor growth. The model-level result supports colorectal tumor growth suppression in vivo but does not establish a human therapeutic dose. Product information
• In a study of seven human hepatocellular carcinoma cell lines, G007-LK suppressed colony-forming growth in a dose-dependent manner and reduced YAP-associated signaling. The study also reported increased AMOTL1 and AMOTL2 proteins after tankyrase inhibition. Jia et al., 2017

Why this cross-domain matters, maturity, and limitations

The colorectal and hepatocellular carcinoma findings are related by tankyrase biology but are not interchangeable. The colorectal models emphasize AXIN stabilization and β-catenin turnover. The hepatocellular carcinoma study emphasizes AMOTL1/2 stabilization and YAP/TAZ regulation. The HCC evidence is peer-reviewed and open access, but it remains preclinical evidence from cell and colony assays. It does not prove that G007-LK will produce the same dominant mechanism in every APC-mutant colorectal tumor or in patients Jia et al., 2017.

Applications, Limits & Misconceptions

G007-LK is suited to experiments that ask whether TNKS1/2 activity contributes to a measurable signaling or cancer-cell phenotype. In APC mutation colorectal cancer research, useful readouts include β-catenin localization, AXIN1/2 abundance, Wnt reporter activity, proliferation, colony formation, and viability. A strong design measures at least one proximal marker, such as AXIN1/2 or TNKS1/2 protein, together with one functional endpoint.

The compound is also useful for tankyrase inhibitor for Wnt signaling modulation studies. The ST-Luc response can report pathway suppression, while β-catenin immunoblotting or imaging can test whether the response is accompanied by protein-level changes. These endpoints should not be conflated. Reporter inhibition alone does not establish the molecular cause of the response.

The HCC study expands the research scope to Hippo signaling. In those models, G007-LK and XAV-939 reduced proliferation and were reported to synergize with MEK or AKT inhibitors. Such combination observations are model-specific. They do not establish a general combination rule or clinical benefit Jia et al., 2017.

Common Pitfalls or Misconceptions

• Confusing IC50 values with recommended dosing. The 25 nM and 46 nM enzyme values describe biochemical auto-poly(ADP-ribosyl)ation assays. They do not define a universal cell-culture concentration or animal dose.
• Assuming every β-catenin decrease proves direct β-catenin binding. The reported mechanism is consistent with TNKS1/2 inhibition, AXIN stabilization, and enhanced destruction-complex activity. G007-LK should not be described as a direct β-catenin degrader without additional binding evidence.
• Assuming APC mutation guarantees response. APC-mutant SW480 cells provide a relevant model, but genotype alone does not predict identical pathway dependence across colorectal cancer lines.
• Using water or ethanol as the stock solvent. The product information reports DMSO solubility of at least 26.5 mg/mL and insolubility in water and ethanol. Solvent changes can cause precipitation and alter the effective concentration.
• Translating xenograft results directly to patients. The 20–40 mg/kg COLO-320DM mouse-model benchmark is preclinical and does not establish safety, pharmacokinetics, or human efficacy.

Workflow Integration & Parameters

A reproducible experiment should connect compound identity, solvent handling, pathway engagement, and phenotype. Use matched vehicle controls and record the final DMSO percentage in every treatment condition. Interpret a phenotype more confidently when pathway markers and functional outputs change in the same direction.

Protocol Parameters

• Compound identity: Use G007-LK, SKU B5830, and document the lot, preparation date, and final assay concentration.
• Stock solvent: Prepare the stock in DMSO within the reported solubility of ≥26.5 mg/mL. Do not use water or ethanol as the primary stock solvent because the product information describes G007-LK as insoluble in both.
• Cellular pathway model: Wnt3a-induced HEK 293 cells are suitable for ST-Luc reporter benchmarking. APC-mutant SW480 cells are suitable for examining β-catenin localization and degradasome formation.
• Mechanistic readouts: Measure ST-Luc activity, β-catenin distribution, AXIN1/2 abundance, and TNKS1/2 protein levels as separate endpoints. The reported cellular IC50 of 0.05 μM applies specifically to the Wnt3a-induced HEK 293 ST-Luc assay.
• Vehicle control: Keep DMSO exposure matched between treated and control wells. Establish the vehicle tolerance of the selected cell system before interpreting viability changes.
• Exposure design: Use a concentration-response series and a time course selected for the cell line and endpoint. The dossier does not provide one universal incubation time, so timing should be experimentally optimized rather than treated as a fixed product parameter.
• In vivo benchmark: The reported COLO-320DM xenograft study used 20–40 mg/kg. Treat this range as a published model benchmark, not as a dosing recommendation for humans or unsupervised animal work.
• Storage: Store the solid at −20°C. Use prepared solutions for short-term work and follow institutional chemical-handling procedures.

The article G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β... emphasizes nanomolar TNKS1/2 inhibition and APC-mutant colorectal cancer research; this article extends that overview by separating biochemical, cellular, xenograft, and HCC evidence. The workflow guide G007-LK Tankyrase 1/2 Inhibitor: Applied Workflows & Tips focuses on pathway-oriented experimental integration; this article clarifies which reported values are benchmarks and which parameters require local optimization.

Conclusion & Outlook

G007-LK is a selective TNKS1/2 biochemical probe with reported activity in Wnt reporter systems, APC-mutant colorectal cancer models, COLO-320DM xenografts, and HCC cell models. Its central mechanistic sequence is TNKS1/2 inhibition, AXIN1/2 stabilization, and reduced β-catenin signaling in appropriate cellular contexts. The HCC study additionally supports tankyrase-linked Hippo modulation through AMOTL1/2 and YAP signaling.

Future experiments should test pathway engagement and phenotype together, preserve solvent controls, and distinguish model-specific observations from general claims. The available evidence supports G007-LK for mechanistic Wnt/β-catenin and tankyrase biology research. It does not by itself establish clinical efficacy, a human dose, or uniform activity across cancers.